Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial-Reference-Cited by-同舟云学术

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial

Published:2022-12-15 Issue:1 Volume:12 Page:
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Jin Lairun¹,Tang Rong²,Wu Shipo³,Guo Xiling²,Huang Haitao⁴,Hou Lihua³,Chen Xiaoqin⁵,Zhu Tao⁴,Gou Jinbo⁴,Zhong Jin⁵,Pan Hongxing²,Cui Lunbiao²,Chen Yin²,Xia Xin⁶,Feng Jialu⁶,Wang Xue⁴,Zhao Qi⁴,Xu XiaoYu⁷,Li Zhuopei⁶,Zhang Xiaoyin¹,Chen Wei³,Li Jingxin²⁶⁸,Zhu Fengcai¹²⁶⁸^ORCID

Affiliation:

1. School of Public Health, Southeast University, Nanjing, People’s Republic of China

2. National Health Commission (NHC) Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, People’s Republic of China

3. Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, People’s Republic of China

4. Cansino Biologics Inc., Tianjin, People’s Republic of China

5. Donghai County Center for Disease Control and Prevention, Lianyungang, Jiangsu, People’s Republic of China

6. School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China

7. Vazyme Biotech Co., Ltd, Nanjing, People’s Republic of China

8. Institute of Global Public Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, People’s Republic of China

Funder

National Natural Science Foundation of China

Jiangsu Provincial Science Fund for Distinguished Young Scholars

Key Program of Jiangsu Provincial Science and Technology Plan

National Science Foundation for Excellent Young Scholars of China

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2022.2155251

Reference26 articles.

1. WHO. WHO coronavirus (COVID-19) dashboard. [cited 2022 Oct 25]. Available from: https://covid19.who.int/?topicsurvey=v8kj13)&gclid=EAIaIQobCIhMxL2d_4Sv-AIVYRLnCh2ZXwaDEAAYASACEgI9y_D_BwE

2. WHO. COVID-10 vaccine tracker. [cited 2022 Oct 19]. Available from: https://covid19.trackvaccines.org/agency/who/

3. SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond

4. COVID vaccine immunity is waning — how much does that matter?

5. WHO. Interim recommendations for heterologous COVID-19 vaccination schedules. [cited 2022 Oct 14]. Available from: https://www.who.int/news/item/16-12-2021-interim-recommendations-for-heterologous-covid-19-vaccine-schedules

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control;Signal Transduction and Targeted Therapy;2024-09-11

2. Mucosal vaccines for viral diseases: Status and prospects;Virology;2024-05

3. Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study;Emerging Microbes & Infections;2024-04-28

4. Safety, immunogenicity, and protective effective of inhaled COVID‐19 vaccines: A systematic review and meta‐analysis;Journal of Medical Virology;2024-04

5. Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection;Nature Immunology;2024-02-09